Ovid Therapeutics (OVID) Research & Development (2016 - 2026)

Ovid Therapeutics has reported Research & Development for 11 years, with the latest figure at $11.2 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 67.91% year-over-year to $11.2 million; the trailing twelve-month figure through Mar 2026 stood at $30.1 million (down 8.83% YoY), and the FY2025 full-year result was $25.6 million, down 30.42% from the prior year.
• Research & Development for Q1 2026 stood at $11.2 million, up from $6.6 million in the prior quarter.
• The five-year high for Research & Development was $12.6 million in Q2 2024, with the low at $5.2 million in Q3 2022.
• Historically, Research & Development has averaged $7.5 million across 5 years, with a median of $6.6 million in 2025.
• Annual changes were most pronounced in 2022 — Research & Development plunged 54.83% — and 2024, when it surged 109.73%.
• Ovid Therapeutics' Research & Development stood at $5.6 million in 2022, then soared by 91.53% to $10.6 million in 2023, then tumbled by 44.34% to $5.9 million in 2024, then rose by 11.24% to $6.6 million in 2025, then soared by 69.69% to $11.2 million in 2026.
• The last three Research & Development figures came in at $11.2 million (Q1 2026), $6.6 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.